A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

• ClinicalTrials.gov Identifier: NCT02614794
• Recruitment Status: Completed
• First Posted: November 25, 2015
• Results First Posted: September 28, 2020
• Last Update Posted: August 14, 2023
• Sponsor: Seagen Inc.
• Information provided by (Responsible Party): Seagen Inc.

Tracking Information

• First Submitted Date: November 20, 2015
• First Posted Date: November 25, 2015
• Results First Submitted Date: September 4, 2020
• Results First Posted Date: September 28, 2020
• Last Update Posted Date: August 14, 2023
• Actual Study Start Date: January 28, 2016
• Actual Primary Completion Date: September 4, 2019 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 4, 2020)

Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR) [ Time Frame: 34.6 months ]

Defined as the time from the date of randomization to the date of documented disease progression.

• Original Primary Outcome Measures (submitted: November 23, 2015): Progression-free survival (PFS) [CNS and non-CNS] based on independent central review [ Time Frame: 28 months ]

Current Secondary Outcome Measures (submitted: July 26, 2023)

• PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR [ Time Frame: 34.6 months ]
  Defined as the time from the date of randomization to the date of documented disease progression.
• Overall Survival (OS) at Time of Primary Analysis [ Time Frame: 35.9 months ]
  Defined as time from randomization to death from any cause
• Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR [ Time Frame: 34.6 months ]
  Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).
• ORR Per RECIST 1.1 as Determined by Investigator Assessment [ Time Frame: 34.6 months ]
  Defined as achieving a best overall response of confirmed CR or confirmed PR.
• PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis [ Time Frame: 34.6 months ]
  Defined as the time from the date of randomization to the date of documented disease progression
• Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR [ Time Frame: 24.6 months ]
  Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
• DOR Per RECIST 1.1 as Determined by Investigator Assessment [ Time Frame: 33.2 months ]
  Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.
• Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1 [ Time Frame: 34.6 months ]
  Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).
• CBR Per RECIST 1.1 as Determined by Investigator Assessment [ Time Frame: 34.6 months ]
  Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.
• Incidence of Adverse Events (AEs) at Time of Primary Analysis [ Time Frame: 36.1 months ]
  As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
• Frequency of Dose Modifications [ Time Frame: 35.1 months ]
• Incidence of Health Resources Utilization [ Time Frame: 36.1 months ]
  Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.
• Pharmacokinetic Measure: Ctrough of Tucatinib [ Time Frame: 3.5 months ]
  Individual plasma tucatinib concentrations at each sampling time
• Pharmacokinetic Measure: ONT-993 [ Time Frame: 3.5 months ]
  Individual plasma primary metabolite concentrations at each sampling time
• Overall Survival (OS) at Time of Final Analysis [ Time Frame: Up to 60.1 months ]
  Defined as time from randomization to death from any cause
• PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis [ Time Frame: Up to 58.0 months ]
  Defined as the time from the date of randomization to the date of documented disease progression
• Incidence of Adverse Events (AEs) at Time of Final Analysis [ Time Frame: Up to 60.1 months ]
  As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.
• Frequency of Dose Modifications at Time of Final Analysis [ Time Frame: Up to 60.1 months ]

Original Secondary Outcome Measures (submitted: November 23, 2015)

• Progression free survival (PFS) based on investigator assessment [ Time Frame: 28 months ]
• Progression free survival (PFS) (CNS vs. non-CNS) [ Time Frame: 28 months ]
• Time to CNS progression [ Time Frame: 28 months ]
• Objective response rate (ORR) (CNS vs. non-CNS) (%) [ Time Frame: 28 months ]
• Duration of response (CNS vs. non-CNS) [ Time Frame: 28 months ]
• Clinical benefit rate in CNS (the percentage of patients who have achieved complete response, partial response and stable disease as assessed by the RANO-BM criteria) [ Time Frame: 28 months ]
  This is the rate of response assessment of metastatic disease in the Central Nervous System as assessed using the new RANO-BM criteria (Lancet; Vol 16; June 2015; pg 270-278)
• Clinical benefit rate in non-CNS (the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease as assessed by the RECIST 1.1 criteria) [ Time Frame: 28 months ]
  This is the rate of response assessment of non-CNS metastatic disease as assessed using the RECIST 1.1 criteria
• Overall survival (OS) [ Time Frame: 28 months ]
• Safety and Tolerability of ONT-380 in combination with capecitabine and trastuzumab as assessed by comparison of adverse events [ Time Frame: 28 months ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
• Official Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Brief Summary

This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer.

There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo.

The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead.

Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.

Detailed Description

This is a randomized, international, multi-center study in patients with progressive unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, pertuzumab and T-DM1. There are two phases to this trial: the Double-blind Phase and the Unblinded Phase. In the Double-blind phase, participants were randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. In the Unblinded Phase, patients on placebo may be offered tucatinib.

Stratification factors include presence or history of treated or untreated brain metastases or brain lesions of equivocal significance (yes/no), Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), and region of world (US vs. Canada vs. Rest of World).

Safety assessments will be performed at a minimum of once every three weeks throughout study treatment and 30 days after the last dose of study drugs. Laboratory assessments will be performed locally at sites. Left ventricular ejection fraction will be assessed by MUGA or ECHO at screening and once every 12 weeks thereafter.

For the blinded phase, contrast brain MRI was performed at baseline. Efficacy assessments (CT of chest, abdomen and pelvis at a minimum) utilized RECIST 1.1 and included patients with evaluable tumors defined as measurable target lesions and non-measurable non-target lesions. RECIST assessment was performed at baseline, every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter. Repeat MRI of the brain was required on this same schedule only in those patients with brain metastases identified at baseline. All treatment decisions were made based upon investigator assessment. All patients underwent a repeat MRI of the brain within 30 days of the end of treatment unless previously performed at time of disease progression.

For the unblinded phase, RECIST assessments will be performed per standard clinical practice as determined by investigator with a maximum interval of 12 weeks.

• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Masking applied only during the Double-blind phase of the trial. The Unblinded Phase is open-label.

Primary Purpose: Treatment

• Condition: HER2 Positive Breast Cancer

Intervention

• Drug: tucatinib
  300 mg orally twice daily
  Other Name: ONT-380, ARRY-380
• Drug: capecitabine
  1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
  Other Name: Xeloda
• Drug: trastuzumab
  8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
  Other Name: Herceptin, Herceptin Hycleta
• Drug: placebo
  Oral dose twice daily

Study Arms

• Experimental: Tucatinib in combination with capecitabine & trastuzumab
  Tucatinib + capecitabine + trastuzumab
  Interventions:

  • Drug: tucatinib
  • Drug: capecitabine
  • Drug: trastuzumab
• Active Comparator: Placebo in combination with capecitabine & trastuzumab
  Placebo + capecitabine + trastuzumab
  Interventions:

  • Drug: capecitabine
  • Drug: trastuzumab
  • Drug: placebo

Publications *

• Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Munoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021 Aug;153:223-233. doi: 10.1016/j.ejca.2021.05.025. Epub 2021 Jun 29.
• Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
• Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. Erratum In: N Engl J Med. 2020 Feb 6;382(6):586.
• Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Jul;19(7):880-888. doi: 10.1016/S1470-2045(18)30256-0. Epub 2018 May 24.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: May 16, 2019): 612
• Original Estimated Enrollment (submitted: November 23, 2015): 180
• Actual Study Completion Date: August 11, 2022
• Actual Primary Completion Date: September 4, 2019 (Final data collection date for primary outcome measure)

Eligibility Criteria

Double-blind Phase Inclusion Criteria

• Histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology
• Received previous treatment with trastuzumab, pertuzumab, and T-DM1
• Progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy
• Have measurable or non-measurable disease assessable by RECIST 1.1
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• Adequate hepatic and renal function and hematologic parameters
• Left ventricular ejection fraction (LVEF) ≥ 50%

• CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:

  1. No evidence of brain metastases
  2. Untreated brain metastases not needing immediate local therapy

  3. Previously treated brain metastases not needing immediate local therapy

     1. Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy
     2. Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if the following criteria are met:

     i. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment, or time since surgical resection is ≥ 28 days.

     ii. Other sites of disease assessable by RECIST 1.1 are present

  4. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions

Double-blind Phase Exclusion Criteria

• Previously been treated with:

  1. lapatinib within 12 months of starting study treatment (except in cases where lapatinib was given for ≤ 21 days and was discontinued for reasons other than disease progression or toxicity)
  2. neratinib, afatinib, or other investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously
  3. capecitabine (or other fluoropyrimidine) for metastatic disease except in cases where capecitabine was given for < 21 days and was discontinued for reasons other than disease progression or toxicity. Patients who have received capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to starting study treatment are eligible.
• Clinically significant cardiopulmonary disease
• Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease
• Positive for human immunodeficiency virus (HIV)
• Unable for any reason to undergo MRI of the brain
• Have used a strong CYP3A4 or CYP2C8 inhibitor within 5 half-lives of the inhibitor, or a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment
• Have known dihydropyrimidine dehydrogenase deficiency (DPD)

• CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

  1. Any untreated brain lesions > 2.0 cm in size, unless approved by medical monitor
  2. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
  3. Any brain lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria
  4. Known or suspected leptomeningeal disease (LMD)
  5. Poorly controlled seizures Unblinded Phase Crossover Inclusion Criteria - Participants who were randomized to the control arm (placebo + trastuzumab + capecitabine) must meet the following criteria to be eligible to crossover to the experimental arm.
• Have measurable or non-measurable disease assessable by RECIST 1.1
• For patients who were randomized to the control arm and on the long-term follow-up period at the time of crossover screening: have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy.
• Have an ECOG Performance Status of 0 or 1
• Have a life expectancy of at least 6 months
• Have adequate hepatic and renal function and hematologic parameters
• Left ventricular ejection fraction (LVEF) ≥ 50%

• CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:

  i. No evidence of brain metastases ii. Untreated brain metastases not needing immediate local therapy iii. Previously treated brain metastases not needing immediate local therapy

• Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy

• Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if the following criteria are met:

  1. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment, or time since surgical resection is ≥ 28 days.
  2. Other sites of disease assessable by RECIST 1.1 are present Unblinded Phase Crossover Exclusion Criteria - Participants who were randomized to the control arm (placebo + trastuzumab + capecitabine) will be excluded from the crossover to the experimental arm for any of the following reasons.
• Discontinuation of study treatment due to an adverse event while on the double-blind phase of the study. If the adverse event leading to discontinuation of study treatment has resolved, the patient may be allowed to crossover with approval from the medical monitor.

• History of exposure to the following cumulative doses of anthracyclines:

  • Doxorubicin > 360 mg/m^2
  • Epirubicin > 720 mg/m^2
  • Mitoxantrone > 120 mg/m^2
  • Idarubicin > 90 mg/m^2
  • Liposomal doxorubicin > 550 mg/m^2

• History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or biologically similar to tucatinib

  o Exceptions for Grade 1 or 2 infusion related reactions to trastuzumab that were successfully managed, or known allergy to one of the excipients in the study drugs

• Have received treatment with any systemic anti-cancer therapy, non-CNS radiation, or experimental agent within 3 weeks prior to start of crossover therapy

• Any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:

  • Alopecia and neuropathy (must have resolved to ≤ Grade 2)
  • CHF (must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely)
  • Anemia (must have resolved to ≤ Grade 2)
• Have clinically significant cardiopulmonary disease
• Have known myocardial infarction or unstable angina within 6 months prior to start of crossover therapy
• Require therapy with warfarin or other coumarin derivatives
• Inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medications
• Have used a strong CYP2C8 inhibitor within 5 half-lives of the inhibitor or have used a strong CYP2C8 or CYP34A inducer within 5 days prior to start of the crossover (tucatinib) treatment.
• Known dihydropyrimidine dehydrogenase deficiency
• Unable to undergo contract MRI of the brain
• Have evidence within 2 years prior to start of crossover therapy of another malignancy that required systemic treatment
• CNS Exclusion:

• CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

  • Any untreated brain lesions > 2.0 cm in size, unless approved by medical monitor
  • Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
  • Any brain lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria
  • Known or suspected leptomeningeal disease (LMD)
  • Poorly controlled seizures

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Portugal, Spain, Switzerland, United Kingdom, United States

Administrative Information

• NCT Number: NCT02614794
• Other Study ID Numbers: ONT-380-206; 2015-002801-12 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Seagen Inc.
• Original Responsible Party: Cascadian Therapeutics Inc.
• Current Study Sponsor: Seagen Inc.
• Original Study Sponsor: Cascadian Therapeutics Inc.
• Collaborators: Not Provided

Investigators

• Study Director: Jorge Ramos, DO; Seagen Inc.
• Study Director: Corinna Palanca-Wessels, MD, PhD; Seagen Inc.

• PRS Account: Seagen Inc.
• Verification Date: July 2023